Genetically Modified Humans? No Thanks.
By Richard Hayes,
Washington Post
| 04. 15. 2008
In an essay in Sunday's Outlook section, Dartmouth ethics professor Ronald Green asks us to consider a neo-eugenic future of "designer babies," with parents assembling their children quite literally from genes selected from a catalogue. Distancing himself from the compulsory, state-sponsored eugenics that darkened the first half of the last century, Green instead celebrates the advent of a libertarian, consumer-driven eugenics motivated by the free play of human desire, technology and markets. He argues that this vision of the human future is desirable and very likely inevitable.
To put it mildly: I disagree. Granted, new human genetic technologies have real potential to help prevent or cure many terrible diseases, and I support research directed towards that end. But these same technologies also have the potential for real harm. If misapplied, they would exacerbate existing inequalities and reinforce existing modes of discrimination. If more widely abused, they could undermine the foundations of civil and human rights. In the worst case, they could undermine our experience of being part of a single human community with a common human future.
Once we begin...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...